IP Library Granted Patent US 10,584,364
Granted Patent B2
US 10,584,364 · App. 14/046,285 · Granted Mar 10, 2020

Mice that produce hybrid antibodies

Inventors: Andrew J. Murphy (Croton-On-Hudson, NY); George D. Yancopoulos (Yorktown Heights, NY); Margaret Karow (Santa Rosa, CA); Lynn Macdonald (White Plains, NY); Sean Stevens (San Diego, CA); Aris N. Economides (Tarrytown, NY); David M. Valenzuela (Yorktown Heights, NY)
Assignee: Rgeneron Pharmaceuticals, Inc.
C12P21/00A01K67/0275A01K67/0278C07K16/00C07K16/28C07K16/462C12N15/67C12N15/85C12N15/8509C12N15/902C12N15/907A01K2207/15A01K2217/05A01K2227/105A01K2267/01C07K2317/10C07K2317/21C07K2317/24C07K2317/51C07K2317/515C07K2317/56C12N2800/204
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,584,364
App. No.
14/046,285
Granted
Mar 10, 2020
Kind
B2
Abstract

A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.

Claims (3)

1. A transgenic mouse whose genome comprises unrearranged human immunoglobulin heavy chain V, D, and J gene segments, wherein the unrearranged human immunoglobulin heavy chain V, D, and J gene segments in situ replace endogenous mouse immunoglobulin heavy chain V, D, and J gene segments, and the unrearranged human immunoglobulin heavy chain V, D, and J gene segments are operably linked to an endogenous mouse immunoglobulin heavy chain constant region gene, wherein the mouse immunoglobulin heavy chain constant region gene is located at an endogenous mouse immunoglobulin heavy chain constant region locus, wherein the unrearranged human immunoglobulin heavy chain V, D, and J gene segments are present in the germline of the mouse, wherein rearrangement of the unrearranged human immunoglobulin heavy chain V, D, and J gene segments in the mouse results in a rearranged human immunoglobulin heavy chain variable region gene linked to the mouse immunoglobulin heavy chain constant region gene, wherein the mouse in response to an antigen produces a hybrid antibody that comprises a human immunoglobulin heavy chain variable region encoded by the rearranged human immunoglobulin heavy chain variable region gene and a mouse immunoglobulin heavy chain constant region encoded by the mouse immunoglobulin heavy chain constant region gene, wherein mouse V gene segments are present upstream of the unrearranged human immunoglobulin heavy chain variable region gene segments, and wherein the endogenous immunoglobulin enhancer Eμ remains intact upstream of the mouse immunoglobulin heavy chain constant region gene.

2. The mouse of claim 1 , wherein the unrearranged human immunoglobulin heavy chain V, D, and J gene segments are contained on a human genomic DNA fragment that is larger than 20 kb.

3. The mouse of claim 1 , wherein the unrearranged human immunoglobulin heavy chain V, D, and J gene segments are contained on a human genomic DNA fragment that is larger than 100 kb.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2014
From: ECONOMIDES, ARIS N.; VALENZUELA, DAVID M.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 032738/0571 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2014
From: MURPHY, ANDREW J.; YANCOPOULOS, GEORGE D.; KAROW, MARGARET; MACDONALD, LYNN; STEVENS, SEAN
To: REGENERON PHARMACEUTICALS INC.
Reel/Frame 032406/0956 →